The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings.
A number of randomised controlled trials (RCT) have compared control groups with TLC-NOSF dressings (UrgoStart) on chronic wounds. Our aim was to determine whether the clinical trials' results translate into routine management of such wounds, by pooling the data from real-life observational studies.



Observational studies, conducted in France and Germany, evaluating current practices in patients suffering from non-selected chronic wounds treated with a TLC-NOSF dressing were identified. Demographic data, baseline description of wounds and description of their evolution during treatment were extracted and combined. We used two main indicators of clinical outcomes to measure the impact of the TLC-NOSF dressing on this population: time to wound closure and time to 50% reduction of the Pressure Ulcer Scale for Healing (PUSH) score.



In total, data from 10,220 patients were included, with 7903 leg ulcers (LUs), 1306 diabetic foot ulcers (DFUs) and 1011 pressure ulcers (PUs). The overall closure rate was 30.8 % [95 % confidence interval (CI): 29.9-31.7 %]. While the country, patient age, and number of wounds were identified as independent prognosis factors of healing, the most significant were wound duration and baseline area. The delay in initiating TLC-NOSF dressings treatment was also found to be significant. Overall the average time to complete closure was 112.5 days [95%CI: 105.8-119.3] for LUs, 98.1 days [95 %CI: 88.8-107.5] for DFUs and 119.5 days [95%CI: 94.6-144.3] for PUs. Based on a subgroup analysis of the French cohort, time to closure is substantially shorter for wounds treated with the TLC-NOSF dressing as a first-line intervention compared with those where it has been prescribed as a second-line intervention.



Compared with available data on time to complete closure of chronic wounds managed by 'standard' care, the data from this pooled data analysis showed healing time is reduced, which is consistent with the results of RCTs on TLC-NOSF. That these data are in agreement with those from the RCTs is testimony to their generalisability and important for routine practice. This indicates that using TLC-NOSF dressings in routine wound management can reduce the healing time of LUs, DFUs and PUs. These data also suggest that the earlier the decision to use this dressing, the shorter the time to closure, whatever the severity and the nature of these chronic wounds.
Joint Practice For Internal Medicine, General Medicine, Phlebology & Pain Therapy, Hamburg, Germany.
K C
KC
Münter
Geriatric Department, Rotschild University Hospital, APHP, Paris, France.
S
S
Meaume
Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg, Hamburg, Germany.
M
M
Augustin
Department of Dermatology, University Hospital Paris Est, APHP, Paris, France.
P
P
Senet
Vertical, Paris, France.
J C
JC
Kérihuel
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001458:Bandages; D002908:Chronic Disease; D015331:Cohort Studies; D003102:Colloids; D017719:Diabetic Foot / Q000628:therapy*; D005260:Female; D005602:France; D005858:Germany; D006801:Humans; D007871:Leg Ulcer / Q000628:therapy; D008055:Lipids; D008297:Male; D020782:Matrix Metalloproteinases; D008875:Middle Aged; D009844:Oligosaccharides; D003668:Pressure Ulcer / Q000628:therapy*; D011379:Prognosis; D014647:Varicose Ulcer / Q000628:therapy*; D014945:Wound Healing; D055815:Young Adult
D003102:Colloids; D008055:Lipids; D009844:Oligosaccharides; D020782:Matrix Metalloproteinases
MMP modulator; TLC-NOSF dressing; UrgoStart dressing; chronic wounds; healing time; observational study